{Etokimab: A Deep Examination into the 2022981-44-6 Immunoglobulin Etokimab, designated by the specific identifier 2022981-44-6, represents a novel immunoglobulin currently subject to clinical evaluation. This https://www.targetmol.com/compound/etokimab